Acelyrin, Inc. (SLRN)
NASDAQ: SLRN · Real-Time Price · USD
6.30
+0.12 (1.94%)
Oct 22, 2024, 4:00 PM EDT - Market closed

Acelyrin Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021
Period Ending
Jun '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
123.4763.1813.553.56
Research & Development
300.35225.2355.6338.23
Operating Expenses
423.82288.4169.1841.79
Operating Income
-423.82-288.41-69.18-41.79
Interest & Investment Income
38.1730.564.05-
Currency Exchange Gain (Loss)
-0.4-0.4-0.1-
Other Non Operating Income (Expenses)
-8.7410.270.46-0.05
EBT Excluding Unusual Items
-394.79-247.98-64.77-41.84
Merger & Restructuring Charges
49.09-10--
Other Unusual Items
29.4-0.6--
Pretax Income
-299.8-381.64-64.77-41.84
Net Income
-299.8-381.64-64.77-41.84
Net Income to Common
-299.8-381.64-64.77-41.84
Shares Outstanding (Basic)
987021
Shares Outstanding (Diluted)
987021
Shares Change (YoY)
337.21%4410.31%126.58%-
EPS (Basic)
-3.06-5.43-41.59-60.87
EPS (Diluted)
-3.06-5.43-41.59-60.87
Free Cash Flow
-217.49-172-61.52-4.98
Free Cash Flow Per Share
-2.22-2.45-39.50-7.24
EBITDA
-423.56-288.29--
D&A For EBITDA
0.260.12--
EBIT
-423.82-288.41-69.18-41.79
Source: S&P Capital IQ. Standard template. Financial Sources.